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Acute ischemic kidney injury is the most frequent cause of acute renal failure in daily clinical practice. It has become increasingly
recognizedthatmicrovascularendothelialcelldysfunction (ED)inperitubular capillariesinhibitstheprocessofpostischemicrenal
reperfusion. ED can serve as therapeutic target in the management of acute ischemic kidney injury. Postischemic reﬂow can be
restoredbysystemicadministrationofeithermatureendothelialcellsorofendothelialprogenitorcells. Endothelialprogenitorcells
EPCs can be cultured from the peripheral circulation of humans and diﬀerent animals.The cells act vasoprotectively by direct and
indirect mechanisms. The protective eﬀects of EPCs in acute ischemic kidney injury can be stimulated by preincubating the cells
withdiﬀerent agonistic mediators. This paper summarizes the currently available data on strategies to improve the renoprotective
activity of EPCs in acute ischemic kidney injury.
1.EndothelialDysfunction in
AcuteIschemicKidneyInjury
Acute ischemic kidney injury is the most frequent cause
of acute renal failure in daily clinical practice [1]. Despite
the signiﬁcant progress that has been made in the ﬁelds
of intensive care medicine and renal replacement therapy
over the past 30 years, the mortality of acute renal failure
in hospitalized patients still varies from 30 to 70% [1–
3]. Although hypoperfusion of the kidney, resulting from
various pathologic conditions, primarily aﬀects the function
and structure of tubular epithelial cells, it has become
increasingly recognized that microvascular endothelial cell
dysfunction (ED) in peritubular capillaries inhibits the pro-
cess of postischemic renal reperfusion and thereby prolongs
kidney malfunction [4, 5]. First studies came from Flores
et al. [6]: rats that underwent transient renal artery clamping
showed intense swelling ofall cellularelementsin the kidney,
leading to persistent renal hypoperfusion after the end of
ischemia. Such no-reﬂow, which was in part also attributable
to endothelial cell swelling, could eﬀectively be treated by
the injection of hypertonic mannitol solution, but remained
unaﬀected by an equivalent expansion of the extracellular
ﬂuid volume with either isotonic saline or isotonic man-
nitol [7]. Further studies, published in 2001, showed that
ischemia associated endothelial cell dysfunction in addition
can result in permanent damage to peritubular capillaries.
This damage worsens long-term outcome of kidney function
[8, 9]. These data suggested that postischemic renal ED
could potentially serve as new therapeutic target in the
management of acute ischemic kidney injury. Therefore,
newer investigations performed by Yamamoto and Brodsky
[4, 5] focused on the treatment of postischemic ED by
the administration of mature endothelial cells (HUVECs—
human umbilical vein endothelial cells). In vivo micro-
scopic analyses conﬁrmed the aforementioned signiﬁcant
postischemic endothelial cell swelling within the peritubular
capillary network, and in addition showed that complete
normalization of microvascular tissue perfusion occurs as
late as 24 hours after ischemia. In this setting, systemic
administration of HUVECs markedly inhibited endothelial
cell swelling and promoted a faster functional and structural
recovery of the organ. Histologically, injected cells had partly
been incorporated into the endothelial layer of small blood
vessels surrounding the tubularintegrity [4,5].These studies
showed for the ﬁrst time that targeting postischemic ED by2 International Journal of Nephrology
the administration of cells of the endothelial lineage is a true
option in the treatment of acute ischemic kidney injury.
2.EndothelialProgenitorCells
For many years it had been assumed that new blood
vessels in the adult vertebrate organism exclusively develop
as the result of sprouting of preexisting, mature vessels.
This process, named “angiogenesis”, occurs as a result of
diminished oxygen and nutrient supply to tissues [10–12].
The second process by which blood vessels can be generated,
“vasculogenesis”, is typically found during embryogenesis
[13]. The human organs and tissues are formed during the
ﬁrst eight weeks after conception. Less diﬀerentiated pro-
genitor or precursor cells develop into numerous specialized
cell types that build the whole organism. Blood vessel wall
cells are derived from the so-called hemangioblast [14, 15].
The concept of neovascularization has dramatically been
convulsedbythelandmarkstudiesofAsaharaandcolleagues,
published in 1997 [16]. First, CD34+ cells were isolated
from human umbilical vein blood and cultured under
deﬁned conditions. After several days, the cells displayed
phenotypical and functional characteristics of endothelial
cells. Systemic injection of the cells into immunoincompe-
tent animals with hindlimp ischemia signiﬁcantly improved
postischemic function and structure of the reperfused tissue.
Microscopic analysis showed that injected cells had partly
been incorporated into the vessels’ intima. This was the ﬁrst
time the term “endothelial progenitor cells” or EPCs was
introduced. It was also the ﬁrst time that vasculogenesis had
been documented to occur in an adult vertebrate organism.
Meanwhile, numerous studies on the subject have been
published [11–13, 17–29], but, as a matter of fact, the
exact nature of EPCs or, if spoken more provocatively, the
question if EPCs really exist, is still intensively debated
[27, 28]. According to newer concepts of EPC biology, at
least two major populations of “EPCs” can be diﬀerentiated
[27, 28, 30, 31] .T h eﬁ r s ta n db yf a rm o r ei nd e t a i la n a l y z e d
population is represented by cells that primarily develop
from pluripotent hematopoietic stem cells in the bone
marrow. These cells can be isolated from the circulation
of humans and diﬀerent animals. They are cultured on
ﬁbronectin-coated dishes in EBM-2 media [32], they bind
certain types of lectins (BS-1-lectin [mouse] or UE-lectin
[humans]), and they ingest LDL. In culture, the cells
appear after 5–7 days which led to their deﬁnition as “early
outgrowth” EPCs [33–35]. They do express, on one hand
diﬀerent immature or “stem” cell marker molecules such
as CD133, c-Kit, and CD34 [30], and, on the other hand
markers of the endothelial lineage (KDR or Flk-1, CD31,
eNOS). They are most likely identical to the so-called
“colony forming unit endothelial cells” (CFU-ECs). CFU-
ECs can also be cultured from mononuclear blood cells of
various origin. Culturing the cells is a two-step procedure, in
which the cells are ﬁrst plated on ﬁbronectin for two days.
Nonadherent cells are then replated on new dishes where
they give rise to colonies. The colonies consist of rounded
cells in the center, surrounded by spindle-shaped cells in the
periphery [28, 32]. The ongoing controversy about the true
endothelial nature of the cells results from the fact that
after systemic cell treatment of recipient animals, direct cell
incorporation into the endothelial layer is rarely seen [27,
28]. There is no doubt that “early outgrowth” EPCs can act
proangiogenically/antiischemically, since numerous experi-
mental studies proved a pathophysiological role/therapeutic
value in ischemic heart disease, peripheral artery disease,
cerebrovascular disease, and uremia, respectively [19, 36–
46]. Nevertheless, vasoprotection mediated by the cells is
propably more attributable to indirect eﬀects [33]. Rehman
andcolleaguesshowed secretion ofvasoprotectivesubstances
by the cells (VEGF, HGF, IGF-1) [47],andproteomicanalysis
performed by Pula et al. showed that the enzyme thymidine
phosphorylase plays a major role in this process [48]. It
has been concluded that such factors mediate recovery from
endothelial cell dysfunction. Following this concept, “early
outgrowth” EPCs travel to sites of tissue ischemia where
they act in a paracrinic manner. In a newer manuscript,
the authors therefore suggest the term “proangiogenic
hematopoietic cells” as opposed to “endothelial progenitor
cells” [27, 28].
The second EPC population is represented by cells that
share more characteristics with mature endothelialcells [49].
They can also be cultured from blood mononuclear cells
[50].Culturingisperformed oncollagentype2coateddishes
in EBM-2 media [50, 51]. In contrast to “early outgrowth”
EPCs, these cells appearin cultureafter a period of2-3 weeks
(“late outgrowth” EPCs [28, 49–52]). “Late outgrowth”
EPCs do not express hematopoietic but endothelial cell
marker molecules. After systemic cell injection, direct cell
incorporation into the endothelial layer does substantially
occur[28, 53]. The only diﬀerencebetween mature endothe-
l i a lc e l l sa n d“ l a t eo u t g r o w t h ”E P C si st h em u c hm o r e
pronounced in vitro proliferation of the latter. It has recently
been discussed that “late outgrowth” EPCs possibly are
mature endothelial cells, derived from bone marrow residing
vessels, from which they were shed into the circulation [28].
Nevertheless,bothEPCpopulations,“earlyoutgrowth”EPCs
and “late outgrowth” EPCs have been documented to be
involved in neovascularization under both physiological and
pathological conditions [24, 25, 50, 54]. Direct as well as
indirect mechanisms are involved in vessel repair. At the
moment it seems that “early outgrowth” EPCs mostly act
by indirect mechanisms, whereas “late outgrowth” EPCs
predominantly mediate direct endothelial regeneration by
incorporating into the vessels’ walls. Table 1 summarizes the
characteristics of “early outgrowth” EPCs in comparison to
“late outgrowth” EPCs.
3.“EarlyOutgrowth”EPCsin theTreatmentof
AcuteIschemicKidneyInjury
The earlier mentioned studies by Yamamoto and Brodsky
[4, 5] pointed for the ﬁrst time towards a new therapeutic
strategy for treating acute ischemic kidney injury (iAKI).
That is, to target postischemic renal ED in order to optimize
renal reperfusion. Still today, only limited data are available
on the pathophysiological role of EPCs in iAKI. The ﬁrst
study was published by Patschan et al. [24]. FVB/NJ mice,International Journal of Nephrology 3
Table 1: Biologicalproperties of “early outgrowth” as opposed to “late outgrowth” EPCs (see text).
“Early outgrowth” EPCs “Late outgrowth” EPCs
Proliferate in culture after 5–7 days (ﬁbronectin coated dishes) Proliferate in culture after 21 days (collagen type 2 coated dishes)
Express endothelial and hematopoietic cell marker molecules
(CD133, CD45 and CD14) Do not express hematopoietic but endothelial cell marker molecules
Capable of diﬀerentiating into hematopoietic cells Do not diﬀerentiate into hematopoietic cells
Low proliferative activity High proliferative activity
Minimal endothelial tube formation in vitro Signiﬁcant endothelial tube formationin vitro
Proangiogenic activity in vivo Proangiogenic activity in vivo
⇒Proangiogenic hematopoietic cells ⇒ “True” (?) progenitors of endothelial cells
subjected to transient unilateral renal ischemia showed a
rapid EPC mobilization, characterized by substantial splenic
accumulation of the cells. Ischemic preconditioning of
the animals mitigated these eﬀects but promoted direct
homing of mobilized cells into the postischemic kidney,
where they foremost accumulated within the medullopapil-
lary borderzone. EPC-enriched mononuclear cells, isolated
from the kidneys of preconditioned animals protected mice
from acute ischemic renal failure if injected right after
reperfusion. This manuscript was the proof-of-principle
that EPCs (according to the marker molecules that were
used to identify the cells: “early outgrowth” EPCs) can
serve as therapeutic option in the treatment of iAKN.
Further studies revealed that acute renal ischemia mobilizes
endogenous “early outgrowth” EPCs by increasing blood
levelsofuricacid [55].The mechanisms ofuricacid-induced
EPC mobilization were further elucidated by Kuo et al.
[56]. It was demonstrated that monosodium urate (MSU)
in vitro and in vivo induced exocytosis of Weibel-Palade
bodies with subsequent release of IL-8, von Willebrand
factor, and angiopoietin-2 into the culture medium or into
the circulation, respectively. In Toll-like receptor 4 null mice,
acute elevation of uric acid levels by injection of uric acid
did not result in the release of vasomodulatory factors
into the blood. These data suggested that uric acid-induced
exocytosis of Weibel-Palade bodies is mediated through this
receptor. Two years ago, ex vivo expanded syngeneic mouse-
derived “early outgrowth” EPCs were for the ﬁrst time
successfully administered in murine iAKI [25]. Injections of
either 0.5 or 1 × 106 untreated cells after a 30 or 35 minutes
period of ischemia protected recipient animals from acute
renal failure. This was no longer possible if ischemia lasted
for 40 minutes. Histological analysis showed accumulation
of injected cells within theinterstitial area, in closeproximity
to peritubular vessels. Since with longer periods of ischemia
(40minutes),acertainnumber(0.5×106)ofuntreated“early
outgrowth” EPCs did not substantially protect mice from
acute renal failure, the question arose whether therapeutic
strategies could be established in order to increase the
renoprotective capacity or competence of the cells.
4.Increasing RenoprotectiveCompetenceof
“EarlyOutgrowth”EPCsiniAKI
The idea of modifying/increasing the competence of EPCs in
the process of neovascularization arose soon after their ﬁrst
description by Asahara et al. [16]. In an attempt to enhance
inhibition of neointimal hyperplasia, EPCs were genetically
manipulated in orderto overexpress the enzymes endothelial
nitric oxide synthase (eNOS)and heme oxygenase-1 (HO-1)
[57]. Murasawa et al. increased mitogenic activity, migratory
activity, and cell survival of human EPCs by inducing
overexpression of telomerase reverse transcriptase [58].
Increased diﬀerentiation of EPCs into mature endothelial
cells (ECs) was achieved by constitutively overexpressing
protein kinase A. As a result, cellular Flk-1 and neuropilin 1
were signiﬁcantly stimulated [59]. Regardless of the exact
mechanisms by which EPCs (“early outgrowth” or “late
outgrowth” EPCs) mediate vasoprotection in ischemia, it
could be assumed that by increasing the numbers of cells in
postischemic tissues, antiischemic eﬀects must be more pro-
nounced. According to this concept, we sought for a strategy
to stimulate EPC homing (in our studies “early outgrowth”
EPCs) into the reperfused kidney. Integrin molecules rep-
resent one of four major populations of molecules respon-
sible for mediating cell-cell and cell-matrix adhesion. The
other three families of cell adhesion molecules (CAMs)
are represented by cadherins, selectins, and members of
the immunoglobulin superfamily [60, 61]. Each integrin
moleculeiscomposedofoneα-andoneβ-chain, respectively
[62]. The binding speciﬁcity of integrins varies depending
on the structure of these individual subunits [63]. Beta1-
integrins are expressed on the surface of certain subpopula-
tionsofleukocytes[64].Matureendothelialcellsontheother
hand do express diﬀerent members of the immunoglobulin
superfamily (e.g., VCAM-1, PECAM), from which some act
as binding partners of integrins on leukocytes [65]. This
interaction is the prerequisite for transvascular leukocyte
traﬃcking into the perivascular space [64]. In theory,
stimulating integrin-mediated transvascular cell migration
wouldincreasethenumbersofcellsleavingthebloodstream.
Recently, the substance 8-pCPT-2 -O- Me-cAMP (8-O-
cAMP) has been documented to increase migratory activity
of EPCs by agonizing integrins [66]. 8-O-cAMP activates
the so-called cAMP-Epac-Rap-1 signal transduction cascade,
which has been shown to be critically involved in regulating
cell adhesion events [67]. In order to analyze whether 8-
O-cAMP would increase the cells’ renoprotective activity
through stimulating the integrin system, we pretreated
syngeneic murine EPCs with the substance [25]. Sytemically,
injection of pretreated cells into postischemic C57Bl/6N
mice completely protected animals from acute ischemic4 International Journal of Nephrology
Renal outcome ⇑ Renal outcome ⇓
β1-intergins
In vitro modiﬁed “early
outgrowth” EPCs
–Membrane translocation of
β1-intergins (8-O-cAMP)
–Increased production of
proangiogenic mediator (melatonin)
–VEGF
–Ang-2?
–b-FGF?
–Increased membrane expression/
increased activity of membrane-bound
VE-cadherin?
“early outgrowth” EPCs
–VE-cadherin
–N-cadherin?
Figure 1: Mechanisms that are potentially involved in the stimulation or inhibition of EPC-mediated renoprotection after acute renal
ischemia.Agonisticeﬀects on β1-integrins, as they are induced by the Epac-1 activator 8-O-cAMP, increase renoprotective eﬀects of the cells
by stimulating EPC homing to postischemic tissue sites. Another agonisticmechanism is increased production of vasostabilizingsubstances
(e.g.,VEGF) bythecells. Suchincreasedproduction canbeinduced bycell pretreatment withthehormonemelatonin.In contrast,inhibition
of the VE- and N-cadherin system most likely results in decreased renoprotective competence of EPCs (for further explanation see text).
renal failure. To further conﬁrm this data, we then pre-
treated the cells with combined 8-O-cAMP and the integrin
receptor blocking peptide cyclic arginine-glycine-D-aspartic
acid (cRGD) [68]. Administration of combined pretreated
cells partly abrogated the former eﬀects. Histologically, the
numbers of cells present in the kidneys did not diﬀer
between animals that received 8-O-cAMP and animals that
received 8-O-cAMP/cRGD pretreated cells. It was concluded
that binding of cRGD to integrins, while not signiﬁcantly
decreasing homing of EPCs per se, alters the functional
competence of the cells, which is reﬂected by a reduction
of their renoprotective activity. Single cell analysis of 8-O-
cAMP prestimulated cells revealed cellular redistribution of
β1-integrins towards the cellular surface, the total amount
of β1-integrin expression, which was measured by Western-
Blot analysis, remained stable. Taken together, agonizing
β1-integrins in “early outgrowth” EPCs was identiﬁed as a
ﬁrst pharmacological strategy to increase the renoprotective
competence of the cells in the setting of acute ischemic
kidney injury [25]. Since then, our studies focused (and
still focus) onfurther cell-cell/cell-matrix adhesionprocesses
that could potentially be modiﬁed by the cAMP-Epac-Rap-1
pathway as well. Newer, yet unpublished data indicate that
VE-cadherininhibitionpossiblyplaysaroleinreducing EPC-
mediated renoprotective activity. Angiopoietin-1 and -2 are
endogenous mediators, involved in regulating endothelial
cell growth [69]. They compete with each other in the inter-
action with endothelial Tie-2 [70]. Angiopoietin-1 acts as
Tie-2 agonist,therebystimulating expression of VE-cadherin
in endothelial cells. Endothelial VE-cadherin expression in
factisalsostimulatedbycAMP-Epac-Rappathwayactivation
[71]. Mice that are injected with Angiopoietin-1 pretreated
EPCs show signiﬁcantly higher postischemic serum creati-
nine levels than animals injected with untreated cells if VE-
cadherin is blocked by speciﬁc peptides. The mechanisms
responsible for such worsening of renal function can only
be speculated at the moment. In another, quite diﬀerent
approach, “early outgrowth” EPCs were preincubated with
the hormone melatonin (unpublished data). N-acetyl-5-
methoxytryptamine (melatonin), a product of the trypto-
phan metabolism is highly preserved throughout phylogeny.
Itissynthesized inthepinealglandandreleasedintosystemic
circulation in order to exert regulatory roles on circadian
rhythms [72]. It had once been suggested that melatonin
functions as the key regulatory molecule in sleep wake
rhythm. Meanwhile, this concepthas been modiﬁed [73, 74].
Nevertheless, it has been documented that the hormone
is involved in numerous physiological events including the
detoxiﬁcation of free radicals and their related oxygen
derivatives[72]. Melatonin mediates its eﬀectsexclusivelyvia
interacting with MT-1 and -2 receptors expressed by cells of
various phenotype [75]. The hormone has been shown toInternational Journal of Nephrology 5
improve proangiogenic activity of mesenchymal stem cells
in vitro [76]. If 0.5 × 106 melatonin pretreated EPCs were
injected into mice after a 40 minutes period of bilateral
renal ischemia, renal function did not diﬀer from untreated
(nonischemic) animals. While melatonin did not have an
inﬂuence on TGF-beta-induced EPC apoptosis or necrosis,
production and secretion of proangiogenic VEGF by the
cells were enhanced after incubation with the hormone. In
contrast, cellular production/release of Angiopoietin-2 and
ﬁbroblast growth factor-2 (FGF-2) remained unaﬀected. In
addition,migratoryactivityofthecellswasstimulated.These
data are currently under review for publication.
5.Summary
Although acute renal ischemia primarily aﬀects the function
and structure of tubular epithelial cells, postischemic ED
within perivascular vessels is an important perpetuating
factor of prolonged postischemic kidney dysfunction. ED-
based therapeutic strategies (e.g., systemic administration
of mature endothelial cells or endothelial progenitor cells)
allow to initiate a faster postischemic reperfusion. “Early
outgrowth” EPCs are a promising tool for treating acute
ischemic kidney injury as the most common cause of acute
renal failure in clinical medicine. It is possible to increase
the cells’ renoprotective activity in this setting by either
increasing their homing to sites of tissue ischemia and/or
by stimulating production/secretion of vasostabilizing medi-
ators such as VEGF (Figure 1). Nevertheless, additional
strategies still need to be established in order to enforce
endogenous EPCs to travel into the postischemic kidney.
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